



A perspective review of phytochemistry and pharmacology of the *Syzygium* genus

Yuniarni U^{*1}, Sukandar E Y¹, Fidrianny I²

¹Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung-40132, Indonesia

²Department of Pharmaceutical Biology, School of Pharmacy, Bandung Institute of Technology, Bandung-40132, Indonesia



Article History:

Received on: 22 Mar 2021

Revised on: 24 Apr 2021

Accepted on: 28 Apr 2021

Keywords:

Syzygium,
Phytochemistry,
Bioactive Compound,
Pharmacological Activity,
Syndrome Metabolic

ABSTRACT

Syzygium is a genus of the Myrtaceae family consisting of large and widespread species from Africa, Asia, Australia, and throughout Oceania and the Pacific region. Some have been cultivated for bearing fruit, ornamental plants and used as traditional medicine. This article excavated *Syzygium* genus which was focused on traditional uses, chemical compounds and biological activities related to treatment of syndrome metabolic. All information was obtained from the scientific literature such as Science Direct, Google Scholar, Scopus and PubMed. Several species were known to have therapeutic potential and used in traditional Chinese medicine, Ayurveda, and herbal medicine in Indonesia. Traditionally, *Syzygium* is known for its therapeutic purposes such as coughing, diarrhea, colds, dysentery, inflammation, pain, skin, and mouth infections. Only a few species have been scientifically studied to verify their usage as traditional medicine. There were many reports on the traditional uses and medicinal effects of *Syzygium* plants, but only a few review articles mainly about phytochemical constituents and their role in pharmacological activities. The present reviews highlight the phytochemical and pharmacological activity of various species of the *Syzygium* genus. The pharmacological activities were discussed in this article focused to metabolic syndrome treatment, such as antidiabetic, antihyperlipidemic, antioxidant and antihypertensive activities. Chemical components isolated mainly flavonoid, terpenoids/sesquiterpenoid, sterols, and lignan. Several bioactive compounds have been identified correlated with pharmacological activity, but the chemical compounds were different for each species.

*Corresponding Author

Name: Yuniarni U

Phone: +62 22 4203368

Email: uyuniarni@gmail.com

ISSN: 0975-7538

DOI: <https://doi.org/10.26452/ijrps.v12i2.4722>

Production and Hosted by

IJRPS | www.ijrps.com

© 2021 | All rights reserved.

INTRODUCTION

Syzygium is a genus that belongs to Myrtaceae family containing more than 1200 species spread worldwide. *Syzygium* species were found from Asia, Africa, Australia, and New Caledonia, commonly found in Southeast Asia. The *Syzygium* genus is an evergreen tree and generally has essential oil. They have aromatic leaves that are rough, shiny and produce flowers, usually pink, yellow, red, or white. *Syzygium cumini*, *Syzygium samarangense*, *Syzygium aromaticum*, and *Syzygium polyanthum* are examples of prevalent species in the community. *Syzy-*

gium genus has been cultivated for medicine, fruit-bearing, and ornamental plants (Mudiana, 2016).

Syzygium genus has been known in many traditional treatments as in Ayurveda, Chinese traditional medicine, and herbal remedy in Indonesia. For example, *S. cumini* is used to treat diabetes, diarrhea, dysentery, and digestion disorders in India (Nahid et al., 2017). In Indonesia, *S. polyanthum* is known to have properties for treating diabetes mellitus, diarrhea, hypertensive, wounds and bacterial infection (Ramadhania et al., 2018). Commonly, several species of Syzygium have been used traditionally to treat non-infectious diseases such as diabetes, hypertension, pain, and inflammation. Several species of Syzygium have been reported in recent studies to treat conditions which associated with metabolic syndrome such as diabetes, hypertension, dyslipidemia, heart disease and as an antioxidant to reduce the progression of this syndrome. Phenolic compounds are common as phytochemical constituents in Syzygium species. This paper reviews a recent study of the phytochemical compounds of the genus Syzygium and pharmacological activity which focused to the metabolic syndrome treatment.

MATERIALS AND METHODS

Data and information in this article were collected from scientific literature database such as Science Direct, Google Scholar, Scopus and PubMed.

RESULTS AND DISCUSSION

Phytochemical Content

There are few species of Syzygium that have been explored phytochemically. Some of these chemical compounds have been known to be responsible for the pharmacological activities of Syzygium. Table 1 reviewed the chemical compounds of different species of Syzygium.

Isolated compounds comprise mainly flavonoid, phenolic compound, terpene/sesquiterpenoid, sterols, and lignan. Some of the same compounds are found in several plants in this genus such as myricetin and myricitrin derivatives were found in *S. aqueum*, *S. forrestii*, *S. grande*, and *S. samarangense*. They were known to have antihyperglycemic and antioxidant activities. β -sitosterol was found in six Syzygium species, namely *S. aromaticum*, *S. cumini*, *S. grande*, *S. kusukusense*, *S. polycephalum*, and *S. siamense*. β -sitosterol was identified to have cytotoxicity activity. Ursolic acid was detected in 4 types of Syzygium, *S. corticosum*, *S. polycephalum*, *S. grande*, and *S. kusukusense*. Like β -sitosterol,

ursolic acid also displayed cytotoxic activity. No literature mentions specific or marker compounds from Syzygium species.

Pharmacological Activities

Metabolic syndrome is a condition which characterized by increasing in risk of heart disease, diabetes, and other health problems that can be co-occurred. Other conditions that give rise to metabolic syndrome are elevated blood pressure and cholesterol and triglyceride abnormalities. The Syzygium genus has been extensively studied for the treatment of metabolic syndrome. Many species in this genus are effective against more than one disease accompanying metabolic syndrome.

Antidiabetic Activity

Different antidiabetic mechanisms have been reported in this plant, including α -amylase and α -glucosidase inhibitors, increasing insulin secretion, acting as an insulin-like effect, or controlling adipocyte metabolism hormones. Flavonoid and phenolic compounds were recognized from the several plant species which contributed to the antidiabetic activity. Furthermore, myricetin derivative from *S. malaccense* and *S. aqueum* was found to be bioactive against diabetes mellitus. Vescalagin from *S. samarangense* and europetin-3-O-rhamnoside from *S. aqueum* were reported as compounds that actively contribute as antidiabetic. This information confirmed the antidiabetic potential of the Syzygium genus. Numerous species of the Syzygium genus have not been explored yet for their antidiabetic potential. Therefore, an examination of other species of Syzygium genus as hypoglycemic is still needed.

Mechanistic action indicated that fruit of *S. cumini* could inhibit α -amylase that is responsible for restraining starch breakdown and lower the levels of postprandial hyperglycemia (Gajera et al., 2017). Myricetin derivatives from *S. malaccense* play a role in antihyperglycemic activity by inhibiting α -glucosidase and α -amylase that are responsible for carbohydrate hydrolysis. Another mechanism of myricetin derivatives to control blood glucose is by exhibiting insulin-like effects (Arumugam et al., 2020). Vescalagin is an active component that is isolated from *S. samarangense* fruit. It had mechanism action as antihyperglycemic effects by enhancing glucose uptake in type 2 diabetic mice. Fasting blood glucose decreased by 44.7% after vescalagin administration for four weeks in diabetic rats (Shen and Chang, 2013).

S. densiflorum extract was given for 28 days can lower blood glucose level and HbA1c in non-fasting

Table 1: Phytochemical content of different species of Syzygium

Species	Compounds	Properties	Ref
<i>S. aqueum</i>	Europetin-3-O-rhamnoside Myricetin-3-O-rhamnoside 4-hydroxybenzaldehyde Myrigalone-B and G, Phloretin	Antihyperglycemic Unknown	(Manaharan <i>et al.</i> , 2012)
<i>S. aromaticum</i>	β -sitosterol, Oleanolic acid lacton β -sitosterol, Oleanolic acid lactone 3 β -hydroxy-11-oxo-olean-12-en-28-oic acid, Flavaellagic acid, Nigricin 3-O- β -D-glucopyranoside 2 α -hydroxyoleanolic acid	Unknown	(Begum <i>et al.</i> , 2014)
<i>S. corticosum</i>	Fouquierol Ursolic acid	Unknown Cytotoxicity	(Ren <i>et al.</i> , 2018)
<i>S. cumini</i>	Lupeol, β sitosterol, Stigmasterol 12-oleanen-3-ol-3 β -acetate	Antidiabetic	(Alam <i>et al.</i> , 2013)
<i>S. forrestii</i>	Myricitrin Myricetin 3-O-(300-Oacetyl)- α -L-rhamnopyranoside Myricetin 3-O-(3"-O-acetyl)- α -L-rhamnopyranoside Myricetin 3-O- β -D-galactopyranoside	Unknown	(Tian <i>et al.</i> , 2011)
<i>S. grande</i>	Myricetin 4'-methyl ether 3-O- β -D-xylopyranoside, Grandoside 4'-methyl ether 3-O- α -L-rhamnopyranoside, Myricetrin Myricetin 3-O- β -D-glucopyranoside β -sitosterol, β -sitosterol glucoside, Botulin Friedelin, Quadranoside IV, Crotalionoside C, Ursolic acid	Antioxidant: Myricetrin ; Myricetin 3-O- β -D-glucopyranoside	(Samy <i>et al.</i> , 2014)
<i>S. kusukusense</i>	Ursolic acid, 2 α -hydroxybetulinic acid Platanic acid, Betulinic acid, Hyptatic acid A	Cytotoxic Unknown	(Bai <i>et al.</i> , 2014)
<i>S. polyanthum</i>	Hentriacontane, Palmitic acid, Squalene, Phytol, Linalool, α -tocopherol, β -tocopherol, α -pinene, Nerolidol	Unknown	(Rahim <i>et al.</i> , 2017)
<i>S. polycephalum</i>	Ursolic acid, Squalene, Oleanolic acid β -sitosterol	Unknown	(Ragasa <i>et al.</i> , 2014)
<i>S. samarangense</i>	Sysamarins A-E; Myricitrin	Unknown Antioxidant	(Hu <i>et al.</i> , 2018; Sobeh <i>et al.</i> , 2019)
<i>Syzygium siamense</i>	Stigmast-5-ene-3 β ,17 α -diol Stigmast-5-ene-3 β ,7 α -diol Stigmast-5-ene-3 β -ylformate Stigmast-5-ene-3-one, Stigmast-5-ene-7amethoxy-3 β -ol, 3 β -sitostanol, 3 β -sitosterol	cytotoxicity	(Chumkaew <i>et al.</i> , 2010)
<i>S. szemaense</i>	Syzygiumursanolides	Antimicrobial	(Xu <i>et al.</i> , 2020)

diabetic rats model. This study also revealed the regeneration of β -cells islets of Langerhans in diabetic group was treated by the extract (Krishnasamy et al., 2016). The antidiabetic effect of *S. aqueum*, as a result, enhances adipogenesis, improves glucose uptake, and increases adiponectin secretion in 3T3-L1 adipocytes. Europetin-3-O-rhamnoside and myricetin-3-O-rhamnoside were bioactive compounds from *S. aqueum* that exhibited insulin-like and insulin-sensitizing effects on adipocytes (Manaharan et al., 2012).

Hypolipidemic Activity

The hypolipidemic effect of *Syzygium* showed a close relationship with antidiabetic effects. Some plants that have antihyperglycemic effect can also lower cholesterol levels such as *S. cumini*, *S. densiflorum*, *S. aromaticum*, *S. malaccense* and *S. samarangense*. The mechanism of reducing lipid profile is unknown. This information indicated that *Syzygium* not only could treat diabetes but also prevent diabetes complications that were related to metabolic syndrome.

Two studies indicated that *S. cumini* declined triglyceride and cholesterol levels, also increased serum HDL (High-Density Lipoprotein) concentration in diabetic rats (Nahid et al., 2017). *S. densiflorum* extract also has an antihyperlipidemic effect at level 800 mg/kg bw (Krishnasamy et al., 2016). Vescalagin which was isolated from *S. samarangense* had a therapeutic value anti-hypertriglyceridemia effect. The earlier report showed that vescalagin also has a beneficial effect on the diabetic disease (Shen and Chang, 2013).

Administration of clove bud powder (*S. aromaticum*) at dose 20-40 g/kg bw decreased lipid concentration serum in diabetic rat. Calculation of the atherogenic index exhibited an increase in value in the diabetic rat group related to the group given by clove bud powder (Adefegha et al., 2014). *S. malaccense* ethanol extract significantly affected the lipid profile by decreasing total cholesterol level and raising HDL cholesterol. The total serum cholesterol was 57.23 mg/dl in *S. malaccense* group and 95.08 mg/dl in the diabetic control. The HDL value was 66.90 mg/dl in *S. malaccense* group and 42.45 mg/dl in the diabetic group (Bairy et al., 2005).

Cardioprotective and Thrombolytic Activity

Cardiomyopathy is one of the risks for diabetic patients caused by up-regulation of reactive oxygen species (ROS). *S. cumini* ethanolic extract exhibit 34% clot lysis from clotted blood in the thrombolytic activity test. This result showed that *S. cumini* pos-

sessed moderate thrombolytic activity (Barbhuiya and Godiya, 2019). The effect of the thrombolytic and cardioprotective activity of *S. cumini* was beneficial for diabetic patients to prevent complications of heart disease.

Antioxidant and Hepatoprotective Activity

Syzygium genus had antioxidant activity through scavenging free radicals and improving metabolism and activity enzyme. Several bioactive compounds have been isolated from *Syzygium* species was indicated to have antioxidant activity. The flavonoid, phenolic compounds, anthocyanin, and essential oils from *Syzygium* species inhibited free radicals. Some of *Syzygium* species have been investigated, potential preventing diabetic retinopathy due to the antioxidant activity.

S. calophyllifolium extract could maintain antioxidant levels in vivo (superoxide dismutase; glutathione reductase and glutathione levels) compared to normal control. Antioxidant levels in vivo in type-2 diabetic rats showed declining in values after 28th days of the examination (Chandran et al., 2016). Administration of *S. densiflorum* extract in diabetic rats revealed rising in SOD (superoxide dismutase), CAT (catalase), and GSH (glutathione) activity (Krishnasamy et al., 2016).

As an active component of *S. malaccense*, myricitrin indicated the potent antioxidant and was useful for controlling diabetes mellitus and its related problems. Myricetin derivatives could prevent diabetic retinopathy in ARPE-19 (retinal pigment epithelium) cells by reducing intracellular reactive oxygen species (ROS) (Arumugam et al., 2020).

Research by Sobeh et al. (2019) displayed that 3,5-di-O-methyl gossypetin from *S. samarangense* had antioxidant activity. This compound worked as an antioxidant by activating the nuclear transcription factor-2 (Nrf-2) pathway, increasing antioxidant proteins expression, for example, HO-1 and Mn-SOD-3.

Antihypertensive Activity

One of the uses of traditional medicine *Syzygium* was for treating hypertension. *S. polyanthum* and *S. guineense* have been evaluated for antihypertensive activity. *S. polyanthum* leaves extract induced hypotension by involving α , β -adrenergic. Cholinergic receptors (Ismail et al., 2013) and *S. guineense* played a major role in antihypertension by dilating blood vessels (Ayele et al., 2010). *S. gratum* could decrease blood pressure in rat model after two weeks of treatment with the extract. It due to the extract had ability to improve endothelial vascular function (Bunbupha et al., 2020), and didn't state

which compound play a role in causing the antihypertensive effect of the *Syzygium* species.

CONCLUSION

In conclusion, only a few species have been examined for the phytochemical compounds from the *Syzygium* genus. The therapeutic effect that was often reported from the *Syzygium* genus as antidiabetic. This effect was also supported by research on antioxidants, hypolipidemia, cardioprotective and antihypertensive. Among the *Syzygium* genus, *S. cumini*, *S. aromaticum*, *S. malaccense*, *S. aquaeum*, and *S. samarangense* are the most studied species for the treatment of metabolic syndrome. The research showed that the *Syzygium* species played a role in the antidiabetic treatment and prevented the development and complications of diabetes. Myricetin derivatives were known to be responsible for antihyperglycemic and found in several species of *Syzygium*. Only a few pharmacological analysis categories have been carried out to support the potential traditional uses of the *Syzygium* genus. The *Syzygium* genus needs further investigation regarding other pharmacological activities, bioactive compounds, and its mechanism of action.

Funding Support

The authors would like to thank the Ministry of Research, Technology and Higher Education of the Republic of Indonesia and Indonesia Endowment Fund for Education (LPDP) for the funding and support of this research through the Indonesian Lecturer Excellence Scholarship (BUDI DN).

Conflict of Interest

The authors declare no conflict of interest for this study.

REFERENCES

- Adefegha, S. A., Oboh, G., Adefegha, O. M., Boligon, A. A., Athayde, M. L. 2014. Antihyperglycemic, hypolipidemic, hepatoprotective and antioxidant effects of dietary clove (*Syzygium aromaticum*) bud powder in a high-fat diet/streptozotocin-induced diabetes rat model. *Journal of the Science of Food and Agriculture*, 94(13):2726–2737.
- Alam, A. U., Howlader, M. M. R., Deen, M. J. 2013. Oxygen Plasma and Humidity Dependent Surface Analysis of Silicon, Silicon Dioxide and Glass for Direct Wafer Bonding. *ECS Journal of Solid State Science and Technology*, 2(12):P515–P523.
- Arumugam, B., Palanisamy, U. D., Chua, K. H., Kuppasamy, U. R. 2020. Amelioration of hyperglycemia-induced oxidative damage in ARPE-19 cells by myricetin derivatives isolated from *Syzygium malaccense*. *Journal of Functional Foods*, 67:103844.
- Ayele, Y., Urga, K., Engidawork, E. 2010. Evaluation of in vivo antihypertensive and in vitro vasodilator activities of the leaf extract of *Syzygium guineense* (willd) D.C. *Phytotherapy Research*, 24(10):1457–1462.
- Bai, L. Y., Lin, W. Y., Chiu, C. F., Weng, J. R. 2014. Anti-tumor Activities of Triterpenes from *Syzygium kusukusense*. *Natural Product Communications*, 9(11).
- Bairy, K. L., Sharma, A., Shalini, A. 2005. Evaluation of the hypoglycemic, hypolipidemic and hepatic glycogen raising effects of *Syzygium malaccense* upon streptozotocin induced diabetic rats. *Journal of Natural remedies*, 5(1):46–51.
- Barbhuiya, A., Godiya, R. 2019. Thrombolytic activity of *Syzygium cumini* seed extract: an in-vitro evaluation. *International Journal of Pharmacy and Biological Sciences*, 9(3):204–208.
- Begum, S., Siddiqui, B. S., Khatoon, R., Aftab, F. 2014. Phytochemical studies on *Syzygium aromaticum* Linn. *J. Chem. Soc. Pak*, 36(3):512–516.
- Bunbupha, S., Apaijit, K., Meephat, S., Manesai, P., Prachaney, P., Pakdeechote, P. 2020. *Syzygium gratum* Extract Attenuates Renal Fibrosis in L-NAME Induced-Hypertensive Rats. *Srinagarind Medical Journal*, 35(2):135–140.
- Chandran, R., Parimelazhagan, T., Shanmugam, S., Thankarajan, S. 2016. Antidiabetic activity of *Syzygium calophyllifolium* in Streptozotocin-Nicotinamide induced Type-2 diabetic rats. *Biomedicine & Pharmacotherapy*, 82:547–554.
- Chumkaew, P., Kato, S., Chantrapromma, K. 2010. New cytotoxic steroids from the fruits of *Syzygium siamense*. *Journal of Asian Natural Products Research*, 12(5):424–428.
- Gajera, H. P., Gevariya, S. N., Hirpara, D. G., Patel, S. V., Golakiya, B. A. 2017. Antidiabetic and antioxidant functionality associated with phenolic constituents from fruit parts of indigenous black jamun (*Syzygium cumini* L.) landraces. *Journal of Food Science and Technology*, 54(10):3180–3191.
- Hu, Y. K., Wang, L., Li, Y. Y., Li, M. J., Xu, W., Zhao, Y., Li, F., Zhao, Y. 2018. Five new triterpenoids from *Syzygium samarangense* (Bl.) Merr. et Perry. *Phytochemistry Letters*, 25:147–151.
- Ismail, A., Mohamed, M., Sulaiman, S. A., Ahmad, W. A. N. W. 2013. Autonomic Nervous System Mediates the Hypotensive Effects of Aqueous and Residual Methanolic Extracts of *Syzygium*

- polyanthum(Wight) Walp. var.polyanthum Leaves in Anaesthetized Rats. *Evidence-Based Complementary and Alternative Medicine*, 2013:1–16.
- Krishnasamy, G., Muthusamy, K., Chellappan, D. R., Subbiah, N. 2016. Antidiabetic, anti-hyperlipidaemic, and antioxidant activity of *Syzygium densiflorum* fruits in streptozotocin and nicotinamide-induced diabetic rats. *Pharmaceutical Biology*, 54(9):1716–1726.
- Manaharan, T., Appleton, D., Cheng, H. M., Palanisamy, U. D. 2012. Flavonoids isolated from *Syzygium aqueum* leaf extract as potential antihyperglycaemic agents. *Food Chemistry*, 132(4):1802–1807.
- Mudiana, D. 2016. *Syzygium* diversity in Gunung Baung, East Java, Indonesia. *Biodiversitas Journal of Biological Diversity*, 17(2):733–740.
- Nahid, S., Mazumder, K., Rahman, Z., Islam, S., Rashid, M. H., Kerr, P. G. 2017. Cardio- and hepato-protective potential of methanolic extract of *Syzygium cumini* (L.) Skeels seeds: A diabetic rat model study. *Asian Pacific Journal of Tropical Biomedicine*, 7(2):126–133.
- Ragasa, C. Y., Torres, O. B., Shen, C. C., Lachica, M. K. E. G., Sulit, A. B., Chua, D. B. D. L., Ancheta, A. D. M., Ismail, C. J. B., Bernaldez, F. T. E., Raga, D. D. 2014. Triterpenes from the Leaves of *Syzygium polycepalum*, *S. cumini*, and *S. samarangense*. *Chemistry of Natural Compounds*, 50(5):942–944.
- Rahim, E. N. A. A., Ismail, A., Omar, M. N., Rahmat, U. N., Ahmad, W. A. N. 2017. GC-MS Analysis of Phytochemical Compounds in *Syzygium polyanthum* Leaves Extracted using Ultrasound-Assisted Method. *Pharmacognosy Journal*, 10(1):110–119.
- Ramadhania, N. R., Purnomo, A. S., Fatmawati, S. 2018. Antibacterial activities of *Syzygium polyanthum* wight leaves. *AIP Conference Proceedings*, page 020024.
- Ren, Y., Anaya-Eugenio, G. D., Czarnecki, A. A., Ninh, T. N., Yuan, C., Chai, H.-B., Soejarto, D. D., Burdette, J. E., de Blanco, E. J. C., Kinghorn, A. D. 2018. Cytotoxic and NF- κ B and mitochondrial transmembrane potential inhibitory pentacyclic triterpenoids from *Syzygium corticosum* and their semi-synthetic derivatives. *Bioorganic & Medicinal Chemistry*, 26(15):4452–4460.
- Samy, M. N., Sugimoto, S., Matsunami, K., Otsuka, H., Kamel, M. S. 2014. One new flavonoid xyloside and one new natural triterpene rhamnoside from the leaves of *Syzygium grande*. *Phytochemistry Letters*, 10:86–90.
- Shen, S. C., Chang, W. C. 2013. Hypotriglyceridemic and hypoglycemic effects of vescalagin from Pink wax apple [*Syzygium samarangense* (Blume) Merrill and Perry cv. Pink] in high-fructose diet-induced diabetic rats. *Food Chemistry*, 136(2):858–863.
- Sobeh, M., Petruk, G., Osman, S., Raey, M. A. E., Imbimbo, P., Monti, D. M., Wink, M. 2019. Isolation of Myricitrin and 3,5-di-O-Methyl Gossypetin from *Syzygium samarangense* and Evaluation of their Involvement in Protecting Keratinocytes against Oxidative Stress via Activation of the Nrf-2 Pathway. *Molecules*, 24(9):1839.
- Tian, L. W., Xu, M., Wang, D., Zhu, H. T., Yang, C. R., Zhang, Y. J. 2011. Phenolic constituents from the leaves of *Syzygium forrestii* Merr. and Perry. *Biochemical Systematics and Ecology*, 39(2):156–158.
- Xu, W., Tan, J., Mu, Y., Zheng, D., Huang, X., Li, L. 2020. New antimicrobial terpenoids and phloroglucinol glucosides from *Syzygium szemaoense*. *Bioorganic Chemistry*, 103.